CRIS Current Research Information System

LUGARESI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.787
NA - Nord America 10.712
EU - Europa 7.999
SA - Sud America 1.185
AF - Africa 443
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 32.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.602
VN - Vietnam 3.949
CN - Cina 2.879
SG - Singapore 2.732
GB - Regno Unito 2.512
IT - Italia 1.654
DE - Germania 1.486
HK - Hong Kong 973
BR - Brasile 907
IN - India 628
RU - Federazione Russa 547
SE - Svezia 362
FR - Francia 329
IE - Irlanda 263
ZA - Sudafrica 243
KR - Corea 242
EE - Estonia 185
NL - Olanda 146
UA - Ucraina 129
AR - Argentina 110
FI - Finlandia 106
ID - Indonesia 91
TG - Togo 74
AT - Austria 64
EC - Ecuador 63
CA - Canada 53
CI - Costa d'Avorio 51
JP - Giappone 48
BD - Bangladesh 37
MX - Messico 37
IR - Iran 35
TR - Turchia 35
CO - Colombia 33
CH - Svizzera 32
ES - Italia 27
GR - Grecia 27
JO - Giordania 26
PL - Polonia 25
BG - Bulgaria 22
CL - Cile 21
SC - Seychelles 21
PY - Paraguay 19
UZ - Uzbekistan 17
IQ - Iraq 16
AU - Australia 15
BE - Belgio 15
DO - Repubblica Dominicana 13
HR - Croazia 13
NG - Nigeria 12
AZ - Azerbaigian 10
VE - Venezuela 10
PE - Perù 9
CZ - Repubblica Ceca 8
PH - Filippine 8
RO - Romania 8
UY - Uruguay 8
EG - Egitto 7
IL - Israele 7
LT - Lituania 7
MA - Marocco 7
PK - Pakistan 7
DZ - Algeria 6
KZ - Kazakistan 6
LB - Libano 6
AL - Albania 5
BO - Bolivia 5
MY - Malesia 5
GE - Georgia 4
KE - Kenya 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
GA - Gabon 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RS - Serbia 3
SI - Slovenia 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
EU - Europa 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MG - Madagascar 2
MK - Macedonia 2
NO - Norvegia 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AD - Andorra 1
AO - Angola 1
BY - Bielorussia 1
CR - Costa Rica 1
DJ - Gibuti 1
DK - Danimarca 1
Totale 32.128
Salva come PNG Salva come JPEG
Città #
Southend 2.335
Singapore 1.806
Fairfield 1.402
Ho Chi Minh City 1.055
Ashburn 998
Hong Kong 970
Hanoi 873
Woodbridge 630
Wilmington 597
Seattle 596
Houston 595
Hefei 571
Princeton 533
Ann Arbor 505
Beijing 501
Cambridge 496
Dong Ket 438
Boardman 418
Santa Clara 415
Chandler 351
Dublin 257
Nanjing 242
Seoul 237
Westminster 234
Bologna 205
Berlin 196
Padova 191
Milan 158
Frankfurt am Main 128
Redondo Beach 128
Dallas 123
Los Angeles 123
Saint Petersburg 111
Haiphong 110
Buffalo 106
San Diego 102
Jinan 93
Medford 89
Da Nang 85
Shenyang 82
Ha Long 80
Quận Bình Thạnh 80
Biên Hòa 79
Rome 78
Dearborn 76
São Paulo 76
Lomé 74
Hebei 71
Bremen 69
Nanchang 68
Redmond 62
Changsha 61
Ninh Bình 61
Nuremberg 60
Guangzhou 57
Bengaluru 55
Hải Dương 55
Helsinki 54
Can Tho 53
Thái Nguyên 53
Abidjan 50
Moscow 50
Munich 47
Turin 47
Tianjin 46
Tokyo 45
Shanghai 43
Falls Church 42
Jakarta 42
Zhengzhou 42
Norwalk 41
Vũng Tàu 41
Bắc Ninh 38
Des Moines 38
Rio de Janeiro 38
Jiaxing 37
Bắc Giang 34
Lappeenranta 34
Vinh 33
Florence 32
Phủ Lý 30
Quận Một 30
New York 29
Ningbo 27
Quận Phú Nhuận 27
Taizhou 27
Amman 26
Hangzhou 26
London 26
Haikou 25
Vienna 25
Xi'an 25
Toronto 24
Chicago 23
Lang Son 23
Lấp Vò 23
Thu Dau Mot 23
Guayaquil 22
Yubileyny 22
Phoenix 21
Totale 21.731
Salva come PNG Salva come JPEG
Nome #
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study 2.774
Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis 446
Distonia faringea parossistica non dolorosa: un esordio atipico di sclerosi multipla. 380
Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis 198
The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. 180
Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure 180
Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis 179
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 174
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: A prospective study 156
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study 150
The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. 149
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship 149
eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54 144
A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years 144
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 143
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 143
Anxiety and depression in multiple sclerosis patients around diagnosis 142
When 'good' is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple Sclerosis 141
Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31 141
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 139
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 137
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 136
Assessing robustness of quantitative susceptibility-based MRI radiomic features in patients with multiple sclerosis 134
Decidere la maternità. Un ausilio per le donne con SM 134
Multiparametric MRI dataset for susceptibility-based radiomic feature extraction and analysis 131
Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy 131
The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care system's preparedness 130
Sleep-related disorders and their relationship with MRI findings in multiple sclerosis 129
BREMSO: A simple score to predict early the natural course of multiple sclerosis 128
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 128
Sapere Migliora : informazioni sulla SM per la persona neodiagnosticata 126
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 126
Dissipation of Motor Sleep Inertia and Motor Wake Inertia in Early Relapsing–Remitting Multiple Sclerosis 124
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis 123
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 121
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 120
Beyond disease: Happiness, goals, and meanings among persons with multiple sclerosis and their caregivers 118
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis 116
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 116
The brief international cognitive assessment for multiple sclerosis (bicams): normative values in the Italian population. 116
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry 116
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 115
Development of a short version of MSQOL-54 using factor analysis and item response theory 115
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype 115
A computational platform for MALDI-TOF mass spectrometry data: Application to serum and plasma samples 114
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom 112
Comparative efficacy of switching to natalizumab in active multiple sclerosis 112
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 112
The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. 112
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 111
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 111
Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments 111
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial 111
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study 110
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience 110
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells 110
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 109
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? 109
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 108
Burden and resources in caregivers of people with multiple sclerosis: A qualitative study 108
Predictors of disability worsening in clinically isolated syndrome. 108
Advance Care Planning in Neurodegenerative Disorders: A Scoping Review 108
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. 107
Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. 107
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 107
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. 106
Home-based palliative approach for people with severe multiple sclerosis and their carers: Study protocol for a randomized controlled trial 106
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 106
Disability accrual in primary and secondary progressive multiple sclerosis 105
Cleavage of cystatin C is not associated with multiple sclerosis 105
Fingolimod after natalizumab and the risk of short-term relapse 105
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 104
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories 104
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study 104
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis 103
A comparison of the Brief International Cognitive Assessment for Multiple Sclerosis and a brief repeatable battery in multiple sclerosis patients. 103
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 103
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 103
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 103
Cognitive dysfunction in patients with relapsing-remitting Multiple Sclerosis 102
IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors 102
F response in vascular and degenerative upper motor neuron lesions 102
Risk of secondary progressive multiple sclerosis: A longitudinal study 101
Applying multidimensional computerized adaptive testing to the MSQOL-54: a simulation study 100
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 100
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. 100
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study 100
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 100
Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial 100
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 99
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. 99
Risk of relapse phenotype recurrence in multiple sclerosis. 99
The Italian multiple sclerosis register 99
Editorial: Aging in multiple sclerosis: from childhood to old age, in women and men 98
Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. 97
A comparison of the brief International cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. 97
null 97
Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. 97
Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery 96
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment 95
Totale 15.084
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.734 0 0 0 0 0 64 109 205 244 149 115 848
2021/20223.919 314 350 207 199 448 238 119 372 146 219 517 790
2022/20233.063 357 456 152 395 139 161 166 165 502 170 221 179
2023/20241.130 91 157 86 85 98 101 63 112 55 69 94 119
2024/20255.937 206 1.062 613 452 792 397 361 166 152 168 310 1.258
2025/20268.940 3.410 1.521 1.592 1.190 1.139 88 0 0 0 0 0 0
Totale 33.153